HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
复制标题
接受曲妥珠单抗治疗的 HER2 阳性乳腺癌患者的预后与 HER2 阴性乳腺癌患者相当
DOI：
10.2147/ott.s40851
复制
发表时间：
2013
影响因子：
4
通讯作者：
Wang S
中科院分区：
文献类型：
--
作者：
Qin T;Yuan Z;Peng R;Bai B;Shi Y;Teng X;Liu D;Wang S
目的曲妥珠单抗治疗中国人乳腺癌(BC)的疗效鲜见报道。这项研究旨在比较接受或不接受曲妥珠单抗治疗的HER2阳性BC患者和HER2阴性BC患者的临床结果。患者和方法本研究涉及三组患者。第一组是2002年1月至2010年7月在中山大学癌症中心接受曲妥珠单抗治疗的115名HER2阳性BC患者；第二组是115名未接受曲妥珠单抗治疗的HER2阳性患者的匹配对照组；第三组是115名HER2阴性患者的匹配组，他们在辅助治疗的基础上接受常规治疗。主要终点是3年和5年无病生存(分别为3-DFS和5-DFS)。生存分析采用Kaplan-Meier法、对数列检验和多因素Cox比例风险回归模型。按2002-2006年和2007-2010年两个不同时期分析三组患者存活率的差异。结果中位随访时间为36个月(12~111个月)。HER2阴性组、接受曲妥珠单抗治疗的HER2阳性组和未接受曲妥珠单抗治疗的HER2阳性组的3-DFS率分别为82.6%、89.6%和67.0%。总体研究人群的3-DFS率具有统计学意义(P<；0.001)。进一步分析表明，前两组与第三组的3-DFS差异有统计学意义(P<；0.01)，但前两组之间的差异无统计学意义(P=0.157)。在三组中，2002-2006年期间的3-DFS比率与2007-2010年期间相比没有显著差异。结论本研究进一步证实了曲妥珠单抗治疗HER2阳性可手术BC的有效性。研究还表明，接受曲妥珠单抗治疗的HER2阳性患者与HER2阴性患者之间的3-DFS和5-DFS比率是相似的。
Purpose The efficacy of trastuzumab in Chinese breast cancer (BC) patients has rarely been reported. This study was designed to compare the clinical outcomes of HER2-positive BC patients receiving or not receiving trastuzumab treatment and HER2-negative BC patients. Patients and methods This study involved three groups of patients. The first group was 115 human epidermal growth factor receptor 2 (HER2)-positive BC patients treated with trastuzumab who were enrolled at Sun Yat-sen University Cancer Center between January 2002 and July 2010; the second group was a matched control group of 115 HER2-positive patients who did not receive trastuzumab treatment; the third group was a matched group of 115 HER2-negative patients who received conventional therapy in the adjuvant setting. The primary endpoint was 3-year and 5-year disease-free survival (3-DFS and 5-DFS, respectively). The Kaplan–Meier method, log-rank test, and multivariate Cox proportional hazard regression model were used for survival analysis. The differences in survival rates among the three groups were also analyzed according to two different periods: 2002–2006 and 2007–2010. Results The median duration of follow-up was 36 months (range, 12–111 months). The 3-DFS rates in the HER2-negative group, the HER2-positive group who received trastuzumab treatment, and the HER2-positive group who did not receive trastuzumab treatment were 82.6%, 89.6%, and 67.0%, respectively. The 3-DFS rate for the total study population was statistically significant (P < 0.001). Further analysis indicated a statistically significant difference in 3-DFS between either of the first two groups and the third group (P < 0.01), but the difference between the first two groups was not statistically significant (P = 0.157). Among the three groups, the 3-DFS rates during 2002–2006 did not have a significant difference compared with that during 2007–2010. Conclusion This study has further confirmed the efficacy of trastuzumab for HER2-positive operable BC in Chinese patients. It has also demonstrated that the 3-DFS and 5-DFS rates between HER2-positive patients receiving trastuzumab treatment and HER2-negative patients are comparable.